Daiichi Sankyo
Clinical trials sponsored by Daiichi Sankyo, explained in plain language.
-
Promising drug for rare skin disease falls short in early trial
Disease control TerminatedThis study tested a new drug called DS-2325a in 9 adults with Netherton Syndrome, a rare genetic condition causing severe skin redness, scaling, and barrier problems. The trial aimed to check safety and early signs of effectiveness, but it was terminated early. The main focus was…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New cancer drug trial halted early: what we know
Disease control TerminatedThis early-stage study tested a new drug called DS-9606a in 88 adults with advanced solid tumors that have a specific protein (Claudin-6). The main goal was to check safety and find the right dose. The study was terminated, so results are limited.
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 18, 2026 12:01 UTC